Navigation Links
Travelers’ Hazard- Antihistamines Make Drowsy Driver

A recent report has zeroed in on a potential threat to those on the road- drivers who handle their vehicle// under the influence of anti-allergy drugs.

A survey of almost 5,000 adults by the survey takers-Privilege Insurance found that one in seven suffered from hayfever or other allergies and almost half of these had driven after taking medication.

Many of those questioned said they had lost concentration at the wheel because of side effects such as drowsiness.

Figures included those like 45 per cent of these having driven while taking medication and nearly 18 per cent admitting that their driving was negatively affected as a result of the medication.

Others were that the equivalent of 3.3 million drivers lost concentration at the wheel due to an impaired reaction caused by illness or medication, and a quarter of drivers admitting to rarely or never checking the side-effects of their remedies before setting off. Just under a quarter of drivers believed there was nothing wrong with driving while on hayfever or allergy medication. The report also found that eight in ten drivers would amend their behavior if they discovered a hayfever medicine might affect their driving.

Says Dr James Lawrie, a GP: "Certain types of drugs or even herbal supplements can affect a person's ability to drive safely and if they are combining several over-the-counter drugs, they could be very dangerous on the road. "It's important that drivers always read the label of any medication they plan to take - either prescribed by a doctor or purchased at their local chemist - and discuss possible side-effects with their pharmacist.”
ANN/V
'"/>




Page: 1

Related medicine news :

1. Doctors Not Drowsy When Treating Womens Sleep Issues
2. Doctors Not Drowsy When Treating Women’s Sleep Issue
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Travelers Hazard Antihistamines Make Drowsy Driver

(Date:8/22/2014)... 2014 The regional economy is about ... is on the grow again. The plant will ... 2016 to boost production of the popular Highlander midsize ... overall investment to $4 billion. This step allows Toyota ... additional flexibility to adjust its product mix to meet ...
(Date:8/22/2014)... Americans know little about how Ebola is transmitted and harbor ... United States, a new survey shows. About four in ... a major Ebola outbreak in the United States, and one-quarter ... get sick with the deadly virus in the next year, ... However, those opinions don,t match reality, the Harvard researchers ...
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... that teaches readers how they can use natural methods ... for years has caught the attention of Shane Michaels, ... only a condition that affects the skin, it can ... suffer from it,” reports Michaels. “The intense itching and ...
(Date:8/22/2014)... Epidermal growth factor receptor (EGFR) mutations found in ... of advanced non-small cell lung cancer (NSCLC) patients correlates ... DNA. , EGFR tyrosine kinase inhibitor (TKI) therapy is ... NSCLC, but the standard for determining mutation status is ... be limited or not available. A more abundant and ...
(Date:8/22/2014)... August 22, 2014 Advancements in ... some clinical applications due to their cost-effectiveness, non-invasiveness, ... innovations in ultrasound, such as the evolution of ... to keep the market moving throughout 2014 and ... can enhance not only the point-of-care (POC) testing ...
Breaking Medicine News(10 mins):Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3
... FAIRFAX, Va., Sept. 18 The American Society,for Therapeutic ... growing staff; Barbara Muth is ASTRO,s new director of ... policy analyst., Ms. Muth brings nearly 20 years ... she worked with the American Red Cross for,eight years ...
... HOUSTON, Sept. 18 Today US Oncology, Inc., ... network,announced the appointment of Michael A. Sicuro as ... position Sicuro will lead and manage,the finance function ... financial,analytical, operational, and transactional issues, including accounting,financial reporting, ...
... claim that internationally adopted children can undergo puberty at ... variety of health risks as adults: abdominal obesity, hypertension, ... are internationally adopted children really more at risk? , ... their living conditions up until their adoption," says Hlne ...
... complication of severe burns. Injury to GI function, ... initiator as well as a stimulator for occurrence ... organ dysfunction syndrome following severe burns. With the ... the stereotype of clinical treatment in recent 30 ...
... present brief clinical report showed that Contrast-enhanced ... agent, Sonazoid, can allow surgeons to investigate ... to find new metastases intraoperatively. , ,Contrast-enhanced ... conventional IOUS to identify new occult lesions ...
... an essential role in filling the gap of transplants ... Considering that living related donors are healthy individuals at ... return to quality of life. , A research article ... World Journal of Gastroenterology addresses this question. ...
Cached Medicine News:Health News:ASTRO Names New Research Director, Health Policy Analyst 2Health News:US Oncology Appoints Michael A. Sicuro Executive Vice President and Chief Financial Officer 2Health News:Strategies for preventing gastrointestinal complications in severely burned patients 2Health News:An analysis of the surgical and perioperative complications in right hepatectomies 2
(Date:8/21/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... health, has appointed Holly B. Bauzon as ... Ms. Bauzon has a proven track record in both ... services companies. She has more than 20 years of ... held the position of Director, Lab Services Sales and ...
(Date:8/21/2014)... YORK , Aug. 21, 2014  Publicis Groupe ... Shannon Hartley , Managing Partner and Healthcare Industry Group ... PharmaVoice 100, which recognizes the most inspiring people in ... are leaders in research and development, marketing, technology, creativity, ... agency in 2006 as a partner in its leading ...
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- Inc. magazine today ... third straight year, No. 349 in Health on ... of the nation,s fastest-growing private companies. The list ... important segment of the economy—America,s independent entrepreneurs. Companies ... LinkedIn, Zillow, and many other well-known names gained ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... 2, 2010 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Agency (MHRA) in the UK has completed review of the ... acceptance for BMN 673 for genetically-defined cancers.  The company expects ... of 2011. "BMN 673 has been proven to ...
... THOUSAND OAKS, Calif., Dec. 2, 2010 Amgen (Nasdaq: ... from several key Nplate® (romiplostim) studies at the 52nd Annual ... Dec. 4-7, 2010, in Orlando, Fla. Results from six studies ... purpura (ITP) add to the growing body of data supporting ...
Cached Medicine Technology:MHRA Completes Review of CTA and Issues Notice of Acceptance for BMN 673 for Genetically-Defined Cancers 2MHRA Completes Review of CTA and Issues Notice of Acceptance for BMN 673 for Genetically-Defined Cancers 3Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 2Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 3Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 4Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 5Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 6Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 7Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 8Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 9Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 10Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 11Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 12Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 13Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 14Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 15
Used to introduce large devices for vascular intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Sheath Introducer featuring patented SLIX Valve, rotating collar, kink-resistant cannula and atraumatic tip transitions....
Medicine Products: